Published: 2021-06-22

Comparison of efficacy and safety of topical luliconazole with topical fluconazole against tinea corporis in a tertiary care hospital

E. Seshathri, R. Deepthi Krishna


Background: Dermatophytosis is a common cutaneous infection worldwide with prevalence varying from 20% to 25%. Luliconazole is a newer topical antifungal applied once daily with greater reservoir property in stratum corneum. Objective of the study was to compare the clinical efficacy and safety of luliconazole 1% cream with Fluconazole 1% cream in patients with mild to severe grades of tinea corporis.

Methods: A total of 100 patients with mycologically confirmed tinea corporis were randomised into group A and B respectively. Group A, 50 patients received luliconazole 1% for 2 weeks and group B, 50 patients received fluconazole 1% cream for 4 weeks. Patients were clinically and mycologically evaluated on 0, 2nd and 4th week of treatment and followed up on 8th week for any relapse.

Results: Significant improvement in efficacy was seen in Luliconazole while compared with fluconazole group against tinea corporis infection. Mycological cure and clinical improvement showed significant difference in group A. The safety and tolerability profile of both groups were good and statistically comparable.

Conclusions: Luliconazole 1% cream is found to be safe, effective and tolerable with low incidence of relapse than fluconazole 1% cream.


Luliconazole, Fluconazole, Tinea corporis, Topical cream

Full Text:



Hay RJ, Ashbee HR. Mycology. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 8th ed. London: Wiley-Blackwell. 2010;2:36.1.

Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(4):2-15.

Marques SA, Robles AM, Tortorano AM. Mycoses associated with AIDS in the third world. Med Mycol. 2000;38:269-79.

Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay N. Comparative evaluation of efficacy and safety of topical fluconazole and clotrimazole in the treatment of tinea corporis. J Pak Asso Dermatol. 2012;22(4).

Calvin OM, Thomas JL. Eczema, psoriasis, cutaneous infections, acne and other common skin disorders. In: Fauci, Braunwald, Kasper editors. Harrison’s Principles of Internal Medicine. 17th ed. New York: McGraw-Hill. 2008;1:318.

Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol. 1994;30(5 Pt 1):677-98.

Borgers M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Rev Infect Dis. 1980;2:520-34.

Routt ET, Jim SC, Zeichner JA, Kircik LH. What is new in fungal pharmacotherapeutics? J Drugs Dermatol. 2014;13:391-95.

Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H. In vitro and in vivo anti dermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemothr. 1998;42:967-70.

Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. BMJ. 2012;10;345.

Barnetson RS, Marley J, Bullen M. Comparison of one week of oral terbinafine (250 mg/day) with four weeks of treatment with clotrimazole 1% cream in inter digital tinea pedis. Br J Dermatol. 1998;139:675-8.

Valeant Pharmaceuticals Inc. LUZU (luliconazole) Cream, 1% for topical use. 2013.

Subhash B, Khanna D. Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evidence. 2014:9:113-24.

Suchil P, Gei FM, Robles M. Once weekly oral dose of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis. Clin Exp Dermatol. 1992;17:397-401.

Yim SM, Ko JH, Lee YW. To compare the efficacy and safety of fluconazole cream with flutrimazole cream in the treatment of superficial mycosis: a multicentre, randomised, double-blind, phase III trial. Mycoses. 2010;53:522-9.

Koga H, Tsuji Y, Inoue K, Kanai K, Majima T, Kasai T et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother. 2006;12:163-5.